ArticleJournal of hematology & oncology2022

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8

Gary Shaw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.